Price Alert

Organogenesis Inc. (ORGO)

NASDAQ: ORGO · Real-Time Price · USD

4.58

0.10 (2.23%)

At close: Aug 20, 2025, 3:59 PM

4.50

-1.72%

After-hours: Aug 20, 2025, 06:42 PM EDT

2.23% (1D)

Bid	4.36
Market Cap	581.01M
Revenue (ttm)	458.76M
Net Income (ttm)	-18.63M
EPS (ttm)	-0.14
PE Ratio (ttm)	-32.71
Forward PE	22.62
Analyst	Hold

Ask	4.75
Volume	317,540
Avg. Volume (20D)	879,330
Open	4.41
Previous Close	4.48
Day's Range	4.41 - 4.62
52-Week Range	2.46 - 6.71
Beta	1.77

About ORGO

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol ORGO

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for ORGO stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Next Earnings Release

Organogenesis Inc. is scheduled to release its earnings on Nov 11, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 week ago

+0.44%

Organogenesis Holdings shares are trading lower af... Unlock content with Pro Subscription

3 months ago

-42.7%

Organogenesis Holdings shares are trading lower after the company reported worse-than-expected Q1 financial results.

News

1 week ago · seekingalpha.com

Organogenesis Holdings Inc. (ORGO) Q2 2025 Earnings Call Transcript

Organogenesis Holdings Inc. (NASDAQ:ORGO ) Q2 2025 Earnings Conference Call August 7, 2025 5:00 PM ET Company Participants David C. Francisco - Chief Financial Officer Gary S.

1 week ago · fool.com

ORGO Sales Drop 23%

2 months ago · seekingalpha.com

Organogenesis Holdings: ReNu And New LCD Offer A Rebound Scenario

ORGO's main drivers are its advanced wound-care and surgical biologics that leverage its evidence-rich portfolio. They have a Phase 3 trial on ReNu knee-osteoarthritis with data anticipated by Septemb...